{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:39:29Z","timestamp":1793021969761,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Society for the Promotion of Science Overseas Challenge Program for Young Researchers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Ductal carcinoma in situ (DCIS) associated with invasive carcinoma\u2009\u2264\u20091\u00a0mm in size is defined as DCIS with microinvasion (DCIS\/microinvasion) rather than as invasive breast carcinoma. The number of patients with microinvasion accounts for\u2009&lt;\u20091% of all breast cancer in published studies. As the numbers are limited, the prognostic significance of DCIS\/microinvasion has not been clearly elucidated. This meta-analysis aimed to investigate the survival differences between patients with DCIS\/microinvasion and those with pure DCIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology was performed. We searched three electronic databases (MEDLINE, Cochrane Library, and EMBASE) and included observational studies published in English that contained survival details of patients with either DCIS or DCIS\/microinvasion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study identified 26 studies that described the clinicopathological characteristics of patients in both the DCIS and DCIS\/microinvasion groups. Survival differences were evaluated in 10 of 26 studies. Disease-free survival and loco-regional recurrence-free survival were significantly shorter in patients with DCIS\/microinvasion than in those with DCIS (Hazard ratio, 1.52; 95% confidence interval, 1.11\u20132.08; <jats:italic>p<\/jats:italic>\u2009=\u20090.01 and hazard ratio, 2.53; 95% confidence interval, 1.45\u20134.41; <jats:italic>p<\/jats:italic>\u2009=\u20090.001, respectively). Both overall survival and distant metastasis-free survival tended to be shorter in patients with DCIS\/microinvasion than in patients with DCIS (Hazard ratio, 1.63; 95% CI, 0.63\u20134.23; <jats:italic>p<\/jats:italic>\u2009=\u20090.31 and hazard ratio, 1.85; 95% confidence interval, 0.74\u20134.66; <jats:italic>p<\/jats:italic>\u2009=\u20090.19, respectively) but the difference was not statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our meta-analysis suggests that DCIS\/microinvasion may display more aggressive biological and clinical behavior than pure DCIS, highlighting the potential need for closer follow-up and consideration of adjuvant treatment strategies in DCIS patients with microinvasive disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-022-06800-3","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:12:38Z","timestamp":1669392758000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis"],"prefix":"10.1007","volume":"197","author":[{"given":"Sho","family":"Shiino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binafsha M.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasagu","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-5525","authenticated-orcid":false,"given":"Emad A.","family":"Rakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"6800_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB et al (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290\u2013303","journal-title":"CA Cancer J Clin"},{"key":"6800_CR2","first-page":"110","volume-title":"Microinvasive carcinoma WHO classification of tumours of the breast","author":"KH Allison","year":"2019","unstructured":"Allison KH, Brogi E, Ellis IO et al (2019) Microinvasive carcinoma WHO classification of tumours of the breast, 5th edn. IARC Press, Lyon, pp 110\u2013113","edition":"5"},{"key":"6800_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/cncr.21652","volume":"106","author":"DL Weaver","year":"2006","unstructured":"Weaver DL, Rosenberg RD, Barlow WE et al (2006) Pathologic findings from the breast cancer surveillance consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106:732\u2013742","journal-title":"Cancer"},{"key":"6800_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12253-008-9054-8","volume":"14","author":"S Bianchi","year":"2008","unstructured":"Bianchi S, Vezzosi V (2008) Microinvasive carcinoma of the breast. Pathol Oncol Res 14:105\u2013111","journal-title":"Pathol Oncol Res"},{"key":"6800_CR5","doi-asserted-by":"publisher","first-page":"64182","DOI":"10.18632\/oncotarget.11639","volume":"7","author":"Y Fang","year":"2016","unstructured":"Fang Y, Wu J, Wang W et al (2016) Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget 7:64182\u201364190","journal-title":"Oncotarget"},{"key":"6800_CR6","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1245\/s10434-019-07556-9","volume":"26","author":"CD Champion","year":"2019","unstructured":"Champion CD, Ren Y, Thomas SM et al (2019) DCIS with microinvasion: is it in situ or invasive disease? Ann Surg Oncol 26:3124\u20133132","journal-title":"Ann Surg Oncol"},{"key":"6800_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijrobp.2010.08.027","volume":"82","author":"RR Parikh","year":"2012","unstructured":"Parikh RR, Haffty BG, Lannin D et al (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82:7\u201313","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6800_CR8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1245\/s10434-010-1407-3","volume":"18","author":"KD Yu","year":"2011","unstructured":"Yu KD, Wu LM, Liu GY et al (2011) Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol 18:1342\u20131348","journal-title":"Ann Surg Oncol"},{"key":"6800_CR9","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"6800_CR10","unstructured":"Union for International Cancer Control (2017) TNM Classification of malignant tumours. 8th ed. 151\u2013158"},{"key":"6800_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S0140-6736(95)90982-6","volume":"345","author":"MJ Silverstein","year":"1995","unstructured":"Silverstein MJ, Poller DN, Waisman JR et al (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154\u20131157","journal-title":"Lancet"},{"key":"6800_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/bjc.1957.43","volume":"11","author":"HJ Bloom","year":"1957","unstructured":"Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359\u2013377","journal-title":"Br J Cancer"},{"key":"6800_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19:403\u2013410","journal-title":"Histopathol"},{"key":"6800_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol 38:1346\u20131366","journal-title":"J Clin Oncol"},{"key":"6800_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"key":"6800_CR16","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997\u20134013","journal-title":"J Clin Oncol"},{"key":"6800_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122","journal-title":"J Clin Oncol"},{"key":"6800_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408\u2013414","journal-title":"J Clin Epidemiol"},{"key":"6800_CR19","unstructured":"The Cochrane Collaboration, Oxford, England (2014) Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration. https:\/\/training.cochrane.org\/online-learning\/core-software\/revman"},{"key":"6800_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"6800_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/0471445428","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"2003","unstructured":"Fleiss JL, Levin B, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. John Wiley Series in Probability and Statistics, New York","edition":"3"},{"key":"6800_CR22","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s13277-014-2652-z","volume":"36","author":"L Wang","year":"2015","unstructured":"Wang L, Zhang W, Lyu S et al (2015) Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol 36:2241\u20132248","journal-title":"Tumour Biol"},{"key":"6800_CR23","first-page":"2665","volume":"11","author":"T Pu","year":"2018","unstructured":"Pu T, Zhong X, Deng L et al (2018) Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study. Int J Clin Exp Pathol 11:2665\u20132674","journal-title":"Int J Clin Exp Pathol"},{"key":"6800_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4048\/jbc.2018.21.2.197","volume":"21","author":"M Kim","year":"2018","unstructured":"Kim M, Kim HJ, Chung YR et al (2018) Microinvasive carcinoma versus ductal carcinoma in situ: a comparison of clinicopathological features and clinical outcomes. J Breast Cancer 21:197\u2013205","journal-title":"J Breast Cancer"},{"key":"6800_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjsurg.2013.01.039","volume":"206","author":"GR Sue","year":"2013","unstructured":"Sue GR, Lannin DR, Killelea B et al (2013) Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 206:478\u2013481","journal-title":"Am J Surg"},{"key":"6800_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013831","volume":"98","author":"S Bertozzi","year":"2019","unstructured":"Bertozzi S, Cedolini C, Londero AP et al (2019) Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: retrospective observational study. Medicine (Baltimore) 98:e13831","journal-title":"Medicine (Baltimore)"},{"key":"6800_CR27","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1245\/s10434-019-07693-1","volume":"26","author":"A Mamtani","year":"2019","unstructured":"Mamtani A, Nakhlis F, Downs-Canner S et al (2019) Impact of age on locoregional and distant recurrence after mastectomy for ductal carcinoma in situ with or without microinvasion. Ann Surg Oncol 26:4264\u20134271","journal-title":"Ann Surg Oncol"},{"key":"6800_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/07357907.2020.1715422","volume":"38","author":"J Zheng","year":"2020","unstructured":"Zheng J, Zhou T, Li F et al (2020) Clinic-pathological features of breast ductal carcinoma in situ with micro-invasion. Cancer Invest 38:113\u2013121","journal-title":"Cancer Invest"},{"key":"6800_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10549-017-4572-2","volume":"167","author":"V Sopik","year":"2018","unstructured":"Sopik V, Sun P, Narod SA (2018) Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat 167:787\u2013795","journal-title":"Breast Cancer Res Treat"},{"key":"6800_CR30","doi-asserted-by":"publisher","first-page":"42045","DOI":"10.1038\/srep42045","volume":"7","author":"W Wang","year":"2017","unstructured":"Wang W, Zhu W, Du F et al (2017) The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: a SEER database analysis. Sci Rep 7:42045","journal-title":"Sci Rep"},{"key":"6800_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10549-016-3878-9","volume":"158","author":"Mette S van Ramshorst","year":"2016","unstructured":"van Ramshorst Mette S, van der Heiden-van der Loo Margriet, Dackus Gwen M. H. E, Linn Sabine C, Sonke Gabe S (2016) The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 158:361\u201371","journal-title":"Breast Cancer Res Treat."},{"key":"6800_CR32","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-19-0463","volume":"25","author":"X He","year":"2019","unstructured":"He X, Ji J, Tian M et al (2019) Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer. Clin Cancer Res 25:7388\u20137395","journal-title":"Clin Cancer Res"},{"key":"6800_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4048\/jbc.2020.23.e62","volume":"23","author":"L Bender","year":"2020","unstructured":"Bender L, Kurtz JE, Petit T et al (2020) Adjuvant trastuzumab is required in human epidermal growth factor receptor 2-positive node-negative breast cancer patients regardless of tumour size. J Breast Cancer 23:672\u2013673","journal-title":"J Breast Cancer"},{"key":"6800_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejso.2013.10.020","volume":"40","author":"H Gojon","year":"2014","unstructured":"Gojon H, Fawunmi D, Valachis A (2014) Sentinel lymph node biopsy in patients with microinvasive breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 40:5\u201311","journal-title":"Eur J Surg Oncol"},{"key":"6800_CR35","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2439::AID-CNCR19>3.0.CO;2-J","volume":"85","author":"J Zavotsky","year":"1999","unstructured":"Zavotsky J, Hansen N, Brennan MB et al (1999) Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer 85:2439\u20132443","journal-title":"Cancer"},{"key":"6800_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10434-000-0636-2","volume":"7","author":"N Klauber-DeMore","year":"2000","unstructured":"Klauber-DeMore N, Tan LK, Liberman L et al (2000) Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 7:636\u2013642","journal-title":"Ann Surg Oncol"},{"key":"6800_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1245\/s10434-012-2640-8","volume":"20","author":"DN Margalit","year":"2013","unstructured":"Margalit DN, Sreedhara M, Chen YH et al (2013) Microinvasive breast cancer: ER, PR, and HER-2\/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 20:811\u2013818","journal-title":"Ann Surg Oncol"},{"key":"6800_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-019-05364-z","volume":"178","author":"E Rakovitch","year":"2019","unstructured":"Rakovitch E, Sutradhar R, Lalani N et al (2019) Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat 178:169\u2013176","journal-title":"Breast Cancer Res Treat"},{"key":"6800_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J et al (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135\u2013144","journal-title":"Breast Cancer Res Treat"},{"key":"6800_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jncimonographs\/lgq035","volume":"2010","author":"DC Allred","year":"2010","unstructured":"Allred DC (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010:134\u2013138","journal-title":"J Natl Cancer Inst Monogr"},{"key":"6800_CR41","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.18632\/oncotarget.3162","volume":"6","author":"SY Kim","year":"2015","unstructured":"Kim SY, Jung SH, Kim MS et al (2015) Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget 6:7597\u20137607","journal-title":"Oncotarget"},{"key":"6800_CR42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/ajcp\/106.3.312","volume":"106","author":"NS Goldstein","year":"1996","unstructured":"Goldstein NS, Murphy T (1996) Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. Am J Clin Pathol 106:312\u2013318","journal-title":"Am J Clin Pathol"},{"key":"6800_CR43","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/PAS.0000000000001306","volume":"43","author":"LL Visser","year":"2019","unstructured":"Visser LL, Elshof LE, Van de Vijver K et al (2019) Discordant marker expression between invasive breast carcinoma and corresponding synchronous and preceding DCIS. Am J Surg Pathol 43:1574\u20131582","journal-title":"Am J Surg Pathol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06800-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T07:30:06Z","timestamp":1672990206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6800"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06800-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CQ has received speaker fees from Exact Sciences. SK has received honoraria from Daiichi Sankyo co. ltd, Taiho Pharmaceutical co. ltd, Eli Lilly and Company, MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical, Ltd., Dinow Inc., and Novartis Japan. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used only previously published data and does not include original participants\u2019 data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}